Lyfegen, a Swiss healthtech company focused on drug pricing and market access, reported a busy week marked by product expansion, market development, and growing industry visibility. The company officially launched its AI Contracting Companion at the World Evidence, Pricing and Access Congress 2026, positioning it as a generative AI tool to support complex drug contracting and rebate decisions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The platform is designed to help pharma companies and payers navigate fragmented data, intricate rebate structures, and cross-market pricing interdependencies, while maintaining human oversight in shared decision environments. Lyfegen highlighted particular applicability in rare disease agreements, where high upfront costs and small patient populations demand modular, multi‑mechanism contracts.
The firm also drew attention to risks from most-favored-nation pricing rules, noting that visible list prices can drive launch delays, altered sequencing, or market withdrawal, ultimately limiting patient access. Through new reports and posts, Lyfegen is promoting innovative contracting models and integrated data frameworks as tools for managing MFN exposure and improving market access.
On the commercial front, Lyfegen is executing an intensive 10‑day conference push, with leadership present at EVERSANA’s Pharma Pricing & Contracting Innovation Conference, PharmagoraPlus in Paris, the NICE Conference in Manchester, and the Canadian Institute’s Pathways to Access & Reimbursement forum in Toronto. These events are intended to deepen engagement with payers, regulators, and manufacturers on reimbursement, real‑world evidence, and value‑based access models.
To support this growth, the company added Stephan Beereuter as an Account Executive to strengthen Swiss payer and pharma relationships and hired Elliot Taylor as Senior Market Access and Pricing Analyst. Lyfegen also expanded its recruiting team with two Senior Talent Recruiters, signaling a broader headcount build‑out to meet demand.
The firm’s LinkedIn community surpassed 60,000 followers, underscoring rising interest in drug contracting, market access, and value‑based healthcare. Overall, the combination of AI product rollout, thought leadership on pricing complexity, targeted conference activity, and talent expansion suggests Lyfegen is consolidating its position in AI‑enabled market access technology and laying groundwork for future recurring revenue growth.